- Trial phase
- Approved
- Time to market
- Already approved and commercially available since 2021. Currently marketed by CorMedix following the Melinta acquisition.
- Why 4/10
- KIMYRSA is already FDA-approved and commercially launched with no pending regulatory decision. The next hard catalyst for CorMedix is the REZZAYO sNDA PDUFA decision in Q1 2027, not specific to KIMYRSA. As one of several marketed products in a diversified portfolio, KIMYRSA alone does not drive a binary share-price move.
KIMYRSA is an already-approved, commercial-stage asset within CorMedix's broader portfolio. The next major company-wide catalyst is the REZZAYO sNDA PDUFA decision in Q1 2027, not anything specific to KIMYRSA. Watch for Q4 2026 earnings (likely Feb/Mar 2027) for updates on Melinta portfolio revenue contributions including KIMYRSA, and the Heron Therapeutics acquisition closing (expected Q1 2027).
Price Chart
Executive Summary
KIMYRSA (oritavancin) is an FDA-approved, single-dose IV antibiotic for acute bacterial skin and skin structure infections (ABSSSI), including MRSA. Originally developed and launched by Melinta Therapeutics in 2021, it became part of CorMedix's portfolio through the $300M acquisition of Melinta that closed in September 2025. KIMYRSA is one of seven marketed products CorMedix gained in the deal, alongside the lead product DefenCath and others like REZZAYO and MINOCIN. The drug is already commercialized with no pending regulatory catalysts, making it a steady revenue contributor within a broader, diversified portfolio. CorMedix's stock trades at ~$4.55 (down from a 52-week high of $13.02) with strong analyst support (mean price target $13.80) and recent insider buying.
How It Works
KIMYRSA (oritavancin) is a lipoglycopeptide antibiotic given as a single, one-time intravenous infusion. It works by disrupting the cell wall of certain Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its key advantage is the single-dose regimen, which allows patients with serious skin infections to be treated with one infusion rather than multiple days of daily IV antibiotics, potentially enabling outpatient treatment or earlier hospital discharge.
Trial Status
KIMYRSA was FDA-approved in March 2021 based on clinical trials demonstrating efficacy in ABSSSI. It is a fully commercialized product. No new clinical trials for KIMYRSA are being conducted by CorMedix.
The Two-Sided Case
Upcoming Catalysts
- REZZAYO sNDA PDUFA decision (Q1 2027) - the next major binary catalyst for CorMedix
- Heron Therapeutics asset acquisition closing (expected Q1 2027)
- Q4 2026 and full-year 2026 earnings report (expected Feb/Mar 2027) - will show Melinta portfolio revenue including KIMYRSA contribution
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CorMedix Inc. DEFA14A CRMD ·Originating report